United States · Platforms & data · The Motley Fool

Repligen (RGEN) Q3 2026 Earnings Call Transcript

Published by The Motley Fool · United States 2 h ago

BioLife acquisition bolsters cell therapy as chromatography and proteins surge.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Gentherm (NASDAQ:THRM) Sees Unusually-High Trading Volume on Insider Buying Activity

JetBlue has been losing money for years. It just charted a path to profitability.

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Novartis Raises Guidance After Trial Setbacks Hit Profit

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge